Overview

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if treatment with HQK-1004 and valganciclovir will result in complete or partial responses in patients with EBV-positive lymphoid malignancies or lymphoproliferative disorders.

Phase:

Phase 2

Details

Lead Sponsor:

HemaQuest Pharmaceuticals Inc.

Treatments:

Arginine butyrate
Ganciclovir
Ganciclovir triphosphate
Valganciclovir